Stock Analiz

Bolt Biotherapeutics, Inc. BOLT

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$6.08Market cap $16M
Open the interactive analysis →

Bolt Biotherapeutics, Inc. (BOLT) is a healthcare company listed in the US with a market value of about $16M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$26M, a net margin of -1034.4%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 102% a year, a 5-year average ROIC of -54%.

About Bolt Biotherapeutics

Bolt Biotherapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $231000 in 2020 to $8M in 2025, growth of about 101.6% a year. It was profitable in 0 of the last 6 years in our data. It spends 371% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S6.3
P/B1.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-156.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)0.1%
Revenue growth (5 yrs, per year)101.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2299.1%
ROIC (5-yr avg.)-54.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$3M$8M$8M$8M$6M$1M$231000
Net income-$26M-$33M-$63M-$69M-$88M-$99M-$61M
Free cash flow-$25M-$40M-$61M-$70M-$78M-$59M-$51M
EPS (diluted)$-14.03$-17.85$-33.06$-36.60$-47.20$-59.40$-577.79
Net margin-1034.4%-433.7%-820.8%-878.6%-1537.8%-7824.7%-26289.2%
ROIC—-73.0%-88.6%-45.3%-36.8%-26.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Bolt Biotherapeutics pay a dividend?

Not currently.

Is Bolt Biotherapeutics a good stock to buy?

We do not give buy or sell advice. Bolt Biotherapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.